human primary bronchial epithelial cells hbecs  (ATCC)

Journal: Biochemistry and Biophysics Reports

Article Title: Targeting iRhom2/ADAM17 attenuates COVID-19-induced cytokine release from cultured lung epithelial cells

doi: 10.1016/j.bbrep.2024.101811

Figure Lengend Snippet: (A & B) Cell viability of cultured bronchial epithelial cells in response to ADAM17 and iRhom2 siRNA treatment, respectively. (C & D) Transfection efficacy of ADAM17 siRNA and iRhom2 siRNA, respectively. (E) COVID-19 pseudo-viral particles (SCV2)-induce the release of TNF-α. (F) Pharmacological inhibition of ADAM17 with TAPI-0 inhibits the release of TNF-α. Data are represented as mean ± SEM, *p < 0.05 versus the control group (n = 4).

Article Snippet: Normal human primary bronchial epithelial cells (NHBE, ATCC®, PS-300-010) were cultured to sub-confluence in a complete medium consisting of Airway Epithelial Cell Basal Media (ATCC®, PS-300-030) supplemented with Bronchial/Tracheal Epithelial Cell Growth Kit (ATCC®, PS-300-040) and 1 % penicillin-streptomycin (100 U/ml) and maintained in a 5 % CO 2 incubator at 37 °C.

Techniques: Cell Culture, Transfection, Inhibition, Control

Journal: Biochemistry and Biophysics Reports

Article Title: Targeting iRhom2/ADAM17 attenuates COVID-19-induced cytokine release from cultured lung epithelial cells

doi: 10.1016/j.bbrep.2024.101811

Figure Lengend Snippet: (A) Silencing of ADAM17 and iRhom2 attenuates COVID-19 pseudo-virus (SCV2)-induced expression of ADAM17 in cultured bronchial epithelial cells (representative immunohistochemical images). Scale bar-100 μm (B) Quantification of the relative intensity of ADAM17 staining (n = 6), (C) Silencing of ADAM17 and iRhom2 attenuates ADAM17 activity cultured bronchial epithelial cells challenged with COVID-19 pseudo-virus mean ± SEM, *p < 0.05 versus the control group.

Article Snippet: Normal human primary bronchial epithelial cells (NHBE, ATCC®, PS-300-010) were cultured to sub-confluence in a complete medium consisting of Airway Epithelial Cell Basal Media (ATCC®, PS-300-030) supplemented with Bronchial/Tracheal Epithelial Cell Growth Kit (ATCC®, PS-300-040) and 1 % penicillin-streptomycin (100 U/ml) and maintained in a 5 % CO 2 incubator at 37 °C.

Techniques: Virus, Expressing, Cell Culture, Immunohistochemical staining, Staining, Activity Assay, Control

Journal: Biochemistry and Biophysics Reports

Article Title: Targeting iRhom2/ADAM17 attenuates COVID-19-induced cytokine release from cultured lung epithelial cells

doi: 10.1016/j.bbrep.2024.101811

Figure Lengend Snippet: Silencing of iRhom2 attenuates cytokine release in bronchial epithelial cells challenged with COVID-19 pseudo-virus (SCV2) (A) IL-1α, (B) IL-1β, (C) IL-6, (D) IL-8, (E) TNF-α, (F) IL-13, (G) IL-10, (H) MCP-1, and (I) IFN-γ. Data are presented as mean ± SEM, *p < 0.05 versus the control siRNA + COVID-19 group (n = 3).

Article Snippet: Normal human primary bronchial epithelial cells (NHBE, ATCC®, PS-300-010) were cultured to sub-confluence in a complete medium consisting of Airway Epithelial Cell Basal Media (ATCC®, PS-300-030) supplemented with Bronchial/Tracheal Epithelial Cell Growth Kit (ATCC®, PS-300-040) and 1 % penicillin-streptomycin (100 U/ml) and maintained in a 5 % CO 2 incubator at 37 °C.

Techniques: Virus, Control

Journal: Clinical & Translational Immunology

Article Title: Naturally derived cytokine peptides limit virus replication and severe disease during influenza A virus infection

doi: 10.1002/cti2.1443

Figure Lengend Snippet: LAT8881 treatment of severe IAV infection reduces pulmonary immunopathology. Groups of male C57BL/6 mice received daily i.n. treatment with 20 mg kg −1 of LAT8881 or PBS alone from 1 dpi with 10 4 pfu of HKx31 IAV. BAL fluid was collected at 3 dpi. Levels of LDH (a) , ATP (b) and S100A10 (c) in BAL fluid determined by colorimetric (OD; optical density), luminescent (RLU; raw luminescence units) assays or ELISA. Data are presented as the mean with each data point representing an individual animal. n = 8 per group from one experiment. ** P < 0.005, *** P < 0.001, Student's t ‐test. Groups of male and female C57BL/6 mice received daily i.n. treatment with 20 mg kg −1 of LAT8881 or PBS alone from 1 dpi with 10 4 pfu of HKx31 IAV. Lungs underwent formalin fixation at 3 dpi and histological analysis of H&E‐stained lung tissue sections were performed. (d) Representative images at 10× magnification (scale bar = 100 μm). Lung sections were randomised and scored blind by 3 readers for (e) peribronchial inflammation (scale 0–5), (f) alveolitis (scale 0–5) and (g) epithelial damage (scale 0–4), as described in the Methods. Data are presented as the mean with each data point representing an individual animal. n = 4–8 per group from one experiment. * P < 0.05, ** P < 0.01, only PBS vs LAT8881 shown, one‐way ANOVA with Dunnett's multiple comparisons test.

Article Snippet: Human primary bronchial epithelial cells were cultured under submerged conditions on collagen‐coated flasks (Cat #A1064401; Thermo Fisher Scientific, Waltham, USA) in supplemented bronchial epithelial growth medium (BEGM; Cat #CC‐3170; Lonza, Basel, Switzerland) and were used within four passages.

Techniques: Infection, Enzyme-linked Immunosorbent Assay, Staining